CL2016003271A1 - Métodos para tratar infecciones - Google Patents
Métodos para tratar infeccionesInfo
- Publication number
- CL2016003271A1 CL2016003271A1 CL2016003271A CL2016003271A CL2016003271A1 CL 2016003271 A1 CL2016003271 A1 CL 2016003271A1 CL 2016003271 A CL2016003271 A CL 2016003271A CL 2016003271 A CL2016003271 A CL 2016003271A CL 2016003271 A1 CL2016003271 A1 CL 2016003271A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- treat infections
- approximately
- treat
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA TRATAR, PREVENIR, O REDUCIR EL DE INFECCIONES MICROBIANAS AL MISMO TIEMPO QUE MINIMIZA LOS EFECTOS ADVERSOS GASTROINTESTINALES USANDO UN RÉGIMEN DE DOSIFICACIÓN DE DOS ETAPAS QUE COMPRENDE APROXIMADAMENTE 1 HASTA APROXIMADAMENTE 7 DÍAS DE ADMINISTRACIÓN INTRAVENOSA SEGUIDO POR APROXIMADAMENTE 1 HASTA APROXIMADAMENTE 14 DÍAS DE ADMINISTRACIÓN ORAL DE UN AGENTE ANTIMICROBIANO.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462014790P | 2014-06-20 | 2014-06-20 | |
US201462034468P | 2014-08-07 | 2014-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016003271A1 true CL2016003271A1 (es) | 2017-08-04 |
Family
ID=54868662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016003271A CL2016003271A1 (es) | 2014-06-20 | 2016-12-20 | Métodos para tratar infecciones |
Country Status (17)
Country | Link |
---|---|
US (2) | US20150366858A1 (es) |
EP (1) | EP3157633A4 (es) |
JP (1) | JP2017518354A (es) |
CN (1) | CN106687179A (es) |
AU (1) | AU2015276911A1 (es) |
BR (1) | BR112016029896A2 (es) |
CA (1) | CA2952955A1 (es) |
CL (1) | CL2016003271A1 (es) |
EA (1) | EA201692531A1 (es) |
EC (1) | ECSP16095557A (es) |
IL (1) | IL249616A0 (es) |
MX (1) | MX2016017348A (es) |
PH (1) | PH12016502547A1 (es) |
SV (1) | SV2016005348A (es) |
TW (1) | TW201605447A (es) |
UY (1) | UY36183A (es) |
WO (1) | WO2015196076A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693695A (zh) * | 2014-11-24 | 2016-06-22 | 重庆医药工业研究院有限责任公司 | 一种德拉沙星葡甲胺盐的晶型及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814256A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Feste, schnellzerfallende Cetirizin-Formulierungen |
PT3056492T (pt) * | 2004-10-08 | 2021-12-27 | Abbvie Inc | Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) |
ME02003B (me) * | 2005-04-11 | 2012-12-31 | Abbott Lab | Farmaceutske smeše koje imaju unapređene profile rastvaranja za lekove koji su slabo rastvorljivi |
US20070249577A1 (en) * | 2005-05-10 | 2007-10-25 | Hopkins Scott J | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures |
CN1943561A (zh) * | 2006-08-23 | 2007-04-11 | 北京阜康仁生物制药科技有限公司 | 普卢利沙星口腔崩解片及其制备方法 |
ES2966093T3 (es) * | 2008-09-24 | 2024-04-18 | Melinta Subsidiary Corp | Formulación farmacéutica que contiene un derivado de quinolona |
NZ593345A (en) * | 2008-11-15 | 2013-04-26 | Rib X Pharmaceuticals Inc | Antimicrobial composition comprising a quinolone carboxylic acid derivative and a cyclodextrin |
WO2010096551A2 (en) * | 2009-02-18 | 2010-08-26 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compositions |
TWI641372B (zh) * | 2013-03-15 | 2018-11-21 | 美商梅琳塔有限責任公司 | 使用抗生素治療超重和肥胖患者感染的方法 |
-
2015
- 2015-06-18 TW TW104119696A patent/TW201605447A/zh unknown
- 2015-06-19 US US14/744,671 patent/US20150366858A1/en not_active Abandoned
- 2015-06-19 EP EP15810585.8A patent/EP3157633A4/en not_active Withdrawn
- 2015-06-19 AU AU2015276911A patent/AU2015276911A1/en not_active Abandoned
- 2015-06-19 WO PCT/US2015/036699 patent/WO2015196076A1/en active Application Filing
- 2015-06-19 MX MX2016017348A patent/MX2016017348A/es unknown
- 2015-06-19 EA EA201692531A patent/EA201692531A1/ru unknown
- 2015-06-19 CN CN201580044477.2A patent/CN106687179A/zh active Pending
- 2015-06-19 CA CA2952955A patent/CA2952955A1/en not_active Abandoned
- 2015-06-19 JP JP2016574152A patent/JP2017518354A/ja active Pending
- 2015-06-19 BR BR112016029896A patent/BR112016029896A2/pt not_active IP Right Cessation
- 2015-06-22 UY UY0001036183A patent/UY36183A/es not_active Application Discontinuation
-
2016
- 2016-12-18 IL IL249616A patent/IL249616A0/en unknown
- 2016-12-20 PH PH12016502547A patent/PH12016502547A1/en unknown
- 2016-12-20 CL CL2016003271A patent/CL2016003271A1/es unknown
- 2016-12-20 SV SV2016005348A patent/SV2016005348A/es unknown
- 2016-12-20 EC ECIEPI201695557A patent/ECSP16095557A/es unknown
-
2017
- 2017-09-06 US US15/696,603 patent/US20170368055A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SV2016005348A (es) | 2017-03-02 |
AU2015276911A2 (en) | 2018-04-26 |
PH12016502547A1 (en) | 2017-04-10 |
US20150366858A1 (en) | 2015-12-24 |
JP2017518354A (ja) | 2017-07-06 |
CN106687179A (zh) | 2017-05-17 |
MX2016017348A (es) | 2017-04-06 |
TW201605447A (zh) | 2016-02-16 |
WO2015196076A1 (en) | 2015-12-23 |
EP3157633A1 (en) | 2017-04-26 |
UY36183A (es) | 2016-01-29 |
US20170368055A1 (en) | 2017-12-28 |
EA201692531A1 (ru) | 2017-05-31 |
AU2015276911A1 (en) | 2017-01-12 |
ECSP16095557A (es) | 2017-03-31 |
CA2952955A1 (en) | 2015-12-23 |
BR112016029896A2 (pt) | 2017-08-22 |
IL249616A0 (en) | 2017-02-28 |
EP3157633A4 (en) | 2018-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
GB2541571A (en) | Pharmaceutical compositions | |
CY1122716T1 (el) | Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας | |
CO2017005038A2 (es) | Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma | |
CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
BR112017004153A2 (pt) | métodos para tratamento de infecções por protozoários | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
CR20150505A (es) | Derivado de dihidropiridazin-3,5-diona | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
SV2016005313A (es) | Derivados de carboxamida | |
CL2017000178A1 (es) | Compuestos para usar en el tratamiento antihelmíntico | |
CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
CL2016003271A1 (es) | Métodos para tratar infecciones | |
MY182634A (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
CL2020003153A1 (es) | Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016) | |
AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
CR20160591A (es) | Metodos para tratar infecciones |